GHRP-6 Frequently Asked Questions

GHRP-6 is a synthetic hexapeptide (six amino acids) that stimulates growth hormone release from the anterior pituitary gland. It belongs to the growth hormone secretagogue (GHS) class and acts on the ghrelin/GHS receptor. Peptides Pharma GHRP-6 is formulated at >99% purity in a lyophilized vial for research applications.

GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, triggering growth hormone release through a calcium-dependent signalling pathway. It also stimulates ghrelin-mediated appetite signalling, which distinguishes it from more selective secretagogues like Ipamorelin. Studies indicate GHRP-6 may also increase IGF-1 levels and influence cortisol and prolactin release.

GHRP-6 is studied in research related to growth hormone secretion, appetite regulation, body composition, muscle wasting, gastric motility, cardioprotection, and wound healing. Its potent GH-releasing properties and appetite-stimulating effects make it a versatile tool in endocrine and metabolic research.

Peptides Pharma GHRP-6 is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch is independently verified by HPLC and mass spectrometry analysis. A Certificate of Analysis is provided with every order.

Lyophilized GHRP-6 should be stored at -20°C for long-term storage or at 2-8°C for short-term use. Protect from light and moisture. Reconstituted GHRP-6 should be kept refrigerated at 2-8°C and used within 28 days.

Add bacteriostatic water slowly down the inside wall of the vial to avoid damaging the peptide. Do not shake — gently swirl until fully dissolved. The reconstitution volume should be chosen based on the desired concentration for your research protocol.

Reconstituted GHRP-6 stored at 2-8°C with bacteriostatic water typically remains stable for up to 28 days. Always use aseptic technique when accessing the vial to prevent contamination and preserve the peptide's integrity.

Yes. Peptides Pharma GHRP-6 is supplied strictly for laboratory and research purposes. It is not an approved medicine and is not intended for human therapeutic use. All research should be conducted in accordance with institutional and regulatory requirements.

While both are GH secretagogues acting on the ghrelin receptor, GHRP-6 produces a stronger growth hormone release but also stimulates appetite (via ghrelin mimicry) and can elevate cortisol and prolactin levels. Ipamorelin is more selective, producing a cleaner GH release without these secondary effects. The choice depends on the specific research objectives.

GHRP-6 is commonly studied in combination with GHRH analogues such as CJC-1295 to achieve synergistic GH release through dual-pathway stimulation. This pairing targets both the ghrelin receptor and the GHRH receptor for amplified growth hormone output. Researchers should consult published literature for protocol design.